Venrock Healthcare Capital Partners II L.P. 13D and 13G filings for Inozyme Pharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 8:34 pm Sale | 2023-12-31 | 13G | Inozyme Pharma, Inc. INZY | Venrock Healthcare Capital Partners II L.P. | 0 0.000% | -3,867,749 (Position Closed) | Filing |
| 2023-02-14 4:09 pm Sale | 2022-12-31 | 13G | Inozyme Pharma, Inc. INZY | Venrock Healthcare Capital Partners II L.P. | 3,867,749 9.300% | -197,251 (-4.85%) | Filing |
| 2022-04-29 4:05 pm Purchase | 2022-04-19 | 13G | Inozyme Pharma, Inc. INZY | Venrock Healthcare Capital Partners II L.P. | 4,065,000 9.800% | 4,065,000 (New Position) | Filing |